Hautmann RE, de Petriconi RC, Pfeiffer C, Volkmer BG. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur Urol. 2012;61:1039–47.

Article  PubMed  Google Scholar 

Leow JJ, Chong YL, Chang SL, Valderrama BP, Powles T, Bellmunt J. Neoadjuvant and adjuvant chemotherapy for upper tract urothelial carcinoma: a 2020 systematic review and meta-analysis, and future perspectives on systemic therapy. Eur Urol. 2021;79:635–54.

Article  CAS  PubMed  Google Scholar 

Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19:666–75.

Article  CAS  PubMed  Google Scholar 

Grossman HB, Natale RB, Tangen CM, Speights VO, Vogelzang NJ, Trump DL, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859–66.

Article  CAS  PubMed  Google Scholar 

Lehmann J, Franzaring L, Thüroff J, Wellek S, Stöckle M. Complete long-term survival data from a trial of adjuvant chemotherapy vs control after radical cystectomy for locally advanced bladder cancer. BJU Int. 2006;97:42–7.

Article  PubMed  Google Scholar 

Pfister C, Gravis G, Fléchon A, Chevreau C, Mahammedi H, Laguerre B, et al. Dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin or gemcitabine and cisplatin as perioperative chemotherapy for patients with nonmetastatic muscle-invasive bladder cancer: results of the GETUG-AFU V05 VESPER trial. J Clin Oncol. 2022;40:2013–22.

Article  CAS  PubMed  Google Scholar 

Witjes JA, Bruins HM, Cathomas R, Compérat EM, Cowan NC, Gakis G, et al. European Association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol. 2021;79:82–104.

Article  CAS  PubMed  Google Scholar 

Birtle AJ, Jones R, Chester J, Lewis R, Biscombe K, Johnson M, et al. Improved disease-free survival with adjuvant chemotherapy after nephroureterectomy for upper tract urothelial cancer: final results of the POUT trial. J Clin Oncol. 2024;42:1466–71.

Article  CAS  PubMed  Google Scholar 

Cathomas R, Lorch A, Bruins HM, Compérat EM, Cowan NC, Efstathiou JA, et al. The 2021 updated European association of urology guidelines on metastatic urothelial carcinoma. Eur Urol. 2022;81:95–103.

Article  PubMed  Google Scholar 

Mori K, Yanagisawa T, Fukuokaya W, Iwatani K, Matsukawa A, Katayama S, et al. Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: a systematic review and network meta-analysis. Int J Urol. 2024;31:25–31.

Article  PubMed  Google Scholar 

Yanagisawa T, Kawada T, Quhal F, Bekku K, Laukhtina E, Rajwa P, et al. Impact of sex on the efficacy of immune checkpoint inhibitors in kidney and urothelial cancers: a systematic review and meta-analysis. World J Urol. 2023;41:1763–74.

Article  PubMed  PubMed Central  Google Scholar 

Apolo AB, Ballman KV, Sonpavde GP, Berg SA, Kim WY, Parikh RA, et al. AMBASSADOR Alliance A031501: phase III randomized adjuvant study of pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma (MIUC) vs observation. J Clin Oncol. 2024;42:LBA531.

Article  Google Scholar 

Bajorin DF, Witjes JA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med. 2021;384:2102–14.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bellmunt J, Hussain M, Gschwend JE, Albers P, Oudard S, Castellano D, et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021;22:525–37.

Article  CAS  PubMed  PubMed Central  Google Scholar 

https://www.urotoday.com/conference-highlights/eau-2024/eau-2024-bladder-cancer/150967-eau-2024-extended-follow-up-from-checkmate-274-including-the-first-report-of-overall-survival-outcomes.html.

The PRISMA Extension Statement for Reporting of Systematic Reviews Incorporating Network Meta-analyses of Health Care Interventions: Checklist and Explanations. Ann Intern Med. 2015;162:777–84.

Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.

Article  PubMed  PubMed Central  Google Scholar 

Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343: d5928.

Article  PubMed  PubMed Central  Google Scholar 

Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21:1539–58.

Article  PubMed  Google Scholar 

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.

Article  PubMed  PubMed Central  Google Scholar 

Assel M, Sjoberg D, Elders A, Wang X, Huo D, Botchway A, et al. Guidelines for reporting of statistics for clinical research in urology. Eur Urol. 2019;75:358–67.

Article  PubMed  Google Scholar 

Connor MJ, Shah TT, Smigielska K, Day E, Sukumar J, Fiorentino F, et al. Additional Treatments to the Local tumour for metastatic prostate cancer-Assessment of Novel Treatment Algorithms (IP2-ATLANTA): protocol for a multicentre, phase II randomised controlled trial. BMJ Open. 2021;11: e042953.

Article  PubMed  PubMed Central  Google Scholar 

van Valkenhoef G, Lu G, de Brock B, Hillege H, Ades AE, Welton NJ. Automating network meta-analysis. Res Synth Methods. 2012;3:285–99.

Article  PubMed  Google Scholar 

Woods BS, Hawkins N, Scott DA. Network meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorial. BMC Med Res Methodol. 2010;10:54.

Article  PubMed  PubMed Central  Google Scholar 

Galsky MD, Witjes AA, Gschwend JE, Schenker M, Valderrama BP, Tomita Y, et al. Extended follow-up results from the CheckMate 274 trial. J Clin Oncol. 2023;41:LBA443.

Article  Google Scholar 

Powles T, Assaf ZJ, Degaonkar V, Grivas P, Hussain M, Oudard S, et al. Updated overall survival by circulating tumor DNA status from the phase 3 IMvigor010 trial: adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma. Eur Urol. 2024;85:114–22.

Article  CAS  PubMed  Google Scholar 

Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358: j4008.

Article  PubMed  PubMed Central  Google Scholar 

Skinner DG, Daniels JR, Russell CA, Lieskovsky G, Boyd SD, Nichols P, et al. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol. 1991;145:459–64.

Article  CAS  PubMed  Google Scholar 

Sternberg CN, Skoneczna I, Kerst JM, Albers P, Fossa SD, Agerbaek M, et al. Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial. Lancet Oncol. 2015;16:76–86.

Article  PubMed  Google Scholar 

Kagawa H, Urabe F, Kiuchi Y, Katsumi K, Yamaguchi R, Suhara Y, et al. Real-world outcomes of adjuvant immunotherapy candidates with upper tract urothelial carcinoma: results of a multicenter cohort study. Int J Clin Oncol. 2024;29:55–63.

Article  CAS  PubMed  Google Scholar 

Saito T, Kanao K, Matsumoto K, Fukumoto K, Igarashi D, Takahashi T, et al. New risk stratification for adjuvant nivolumab for high-risk muscle-invasive urothelial carcinoma. BJUI Compass. 2024;5:281–8.

Article  PubMed  Google Scholar 

Zargar H, Zargar-Shoshtari K, Lotan Y, Shah JB, van Rhijn BW, Daneshmand S, et al. Final pathological stage after neoadjuvant chemotherapy and radical cystectomy for bladder cancer-does pT0 predict better survival than pTa/Tis/T1? J Urol. 2016;195:886–93.

Article  CAS  PubMed  Google Scholar 

Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383:1218–30.